6th National Conference on the

FCPA and Anti-Corruption for the Life Sciences Industry

Tuesday, May 08 to Wednesday, May 09, 2012
New York Marriott Downtown, New York, NY
“Johnson & Johnson will pay a $21.4 million penalty to resolve criminal FCPA charges with the DOJ…”

“Johnson & Johnson in $77 Million Global Settlement,” The FCPA Blog, April 2011

“Pfizer will pay more than $60 million to settle alleged violations of the U.S. Foreign Corrupt Practices Act…Spurred by the investigations, companies throughout the industry are developing multimillion-dollar compliance programs…with these settlements the government has created incentives for companies to come forward, not only to cooperate in investigations but also to inform on competitors.

“Pfizer Settlement Offers Window Into Pharmaceutical Industry Probe,” November 2011, Wall Street Journal

The life sciences “industry sweep” is in full swing. Recent high-profile settlements by two large, multi-national pharmaceutical manufacturers for violations of the FCPA make one fact clear – this is only the beginning…

Structured specifically to provide a forum for addressing continuing and emerging areas of focus for FCPA enforcement by the U.S. DOJ and SEC, ACI’s National Conference on FCPA & Anti-Corruption for the Life Sciences Industry is the annual must-attend event for legal and investigative counsel, global compliance officers, and FCPA attorneys, specifically within the life sciences industry. Don’t miss out on this opportunity to learn what steps you should be taking now to take now to proactively protect your company before, during and after the Government comes knocking.

How is your company poised to respond when the time comes to negotiate a settlement with the Government? Are you sure who retains oversight over foreign HCPs, consultants and doctors? What proactive steps are being taken now to minimize the blow from an FCPA settlement?

Don’t miss this opportunity to meet the prosecutors and strategize with top FCPA counsel as you are provided with proactive strategies for fortifying your compliance program in the following key areas:

  • Screening and monitoring foreign third parties, HCPs, doctors and consultants
  • Compliance protocols and internal controls for global life science operations
  • Travel, gifts, entertainment and hospitality
  • Clinical research, physician sponsorships, grants and advisory boards

Ensure your team is equipped with the tools it needs to withstand an FCPA investigation in this era of heightened enforcement. Learn what to do now to minimize your company’s FCPA exposure tomorrow.